ANDA 91427, held by Aurobindo Pharma USA. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 91427 (Paroxetine Hydrochloride), held by Aurobindo Pharma USA, was first approved by FDA on Apr 14, 2011, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 14, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Paroxetine HydrochlorideEQ 37.5MG BASE · tablet, extended release;oral | Paroxetine Hydrochloride | Rx |
| Apr 6, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 6, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 4, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 4, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jul 15, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 27, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 27, 2011 | Supplement 2Labeling | Approved | None posted |
| Jun 24, 2011 | Supplement 1Labeling | Approved | None posted |
| Apr 14, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters